CY2020032I1 - Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια - Google Patents
Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβιαInfo
- Publication number
- CY2020032I1 CY2020032I1 CY2020032C CY2020032C CY2020032I1 CY 2020032 I1 CY2020032 I1 CY 2020032I1 CY 2020032 C CY2020032 C CY 2020032C CY 2020032 C CY2020032 C CY 2020032C CY 2020032 I1 CY2020032 I1 CY 2020032I1
- Authority
- CY
- Cyprus
- Prior art keywords
- microbes
- treatment
- diseases caused
- pleuromutilin derivatives
- pleuromutilin
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- ZRZNJUXESFHSIO-VYTKZBNOSA-N pleuromutilin Chemical class C([C@H]([C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CO)C)C[C@]32[C@H]1C(=O)CC3 ZRZNJUXESFHSIO-VYTKZBNOSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/95—Spiro compounds containing "not free" spiro atoms
- C07C2603/98—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members
- C07C2603/99—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members containing eight-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07450053A EP1972618A1 (en) | 2007-03-20 | 2007-03-20 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| EP08714294A EP2137143B1 (en) | 2007-03-20 | 2008-03-19 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| PCT/AT2008/000097 WO2008113089A1 (en) | 2007-03-20 | 2008-03-19 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2020032I1 true CY2020032I1 (el) | 2020-11-25 |
| CY2020032I2 CY2020032I2 (el) | 2020-11-25 |
Family
ID=38668870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111101198T CY1117482T1 (el) | 2007-03-20 | 2011-12-02 | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια |
| CY2020032C CY2020032I2 (el) | 2007-03-20 | 2020-09-16 | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111101198T CY1117482T1 (el) | 2007-03-20 | 2011-12-02 | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια |
Country Status (32)
| Country | Link |
|---|---|
| US (12) | US20090118366A1 (el) |
| EP (3) | EP1972618A1 (el) |
| JP (2) | JP5479114B2 (el) |
| KR (1) | KR101478593B1 (el) |
| CN (2) | CN104211624B (el) |
| AT (1) | ATE523486T1 (el) |
| AU (1) | AU2008229609B2 (el) |
| BR (1) | BRPI0809023B8 (el) |
| CA (1) | CA2678795C (el) |
| CY (2) | CY1117482T1 (el) |
| DK (2) | DK2137143T3 (el) |
| EA (1) | EA018707B1 (el) |
| ES (2) | ES2375503T3 (el) |
| FI (1) | FIC20200038I1 (el) |
| HK (1) | HK1140185A1 (el) |
| HR (1) | HRP20110869T1 (el) |
| HU (1) | HUS2100001I1 (el) |
| IL (1) | IL200440A (el) |
| LT (1) | LTPA2020531I1 (el) |
| MA (1) | MA31314B1 (el) |
| MY (1) | MY148916A (el) |
| NL (1) | NL301086I2 (el) |
| NO (1) | NO2021002I1 (el) |
| NZ (1) | NZ579011A (el) |
| PL (1) | PL2137143T3 (el) |
| PT (2) | PT2380874T (el) |
| SI (1) | SI2137143T1 (el) |
| TN (1) | TN2009000347A1 (el) |
| TW (1) | TWI406657B (el) |
| UA (1) | UA97836C2 (el) |
| WO (1) | WO2008113089A1 (el) |
| ZA (1) | ZA200905590B (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1808431A1 (en) * | 2006-01-16 | 2007-07-18 | Nabriva Therapeutics Forschungs GmbH | Mutilin derivatives and their use as pharmaceutical |
| EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| EP2159220A1 (en) * | 2008-09-02 | 2010-03-03 | Nabriva Therapeutics AG | Organic compounds |
| WO2010056855A1 (en) * | 2008-11-13 | 2010-05-20 | Teva Pharmaceutical Industries Ltd. | Preparation of retapamulin via its pleuromutilin-thiol precursor |
| EP2390245A1 (en) * | 2010-05-26 | 2011-11-30 | Nabriva Therapeutics AG | Enantiomerically pure amines |
| EP2399904A1 (en) * | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
| EP2433926A1 (en) | 2010-09-09 | 2012-03-28 | Nabriva Therapeutics AG | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes |
| BR112014001057B1 (pt) | 2011-07-15 | 2018-07-03 | Bayer Intellectual Property Gmbh | Derivados de 2,3-difenilvaleronitrilo, processos para a sua preparação e sua utilização enquanto herbicidas e reguladores do crescimento vegetal |
| CN103265487A (zh) * | 2013-06-05 | 2013-08-28 | 北京理工大学 | 截短侧耳素扩环衍生物及其制备方法和用途 |
| CN104803911B (zh) * | 2014-01-23 | 2018-01-05 | 中国科学院上海药物研究所 | 一类截短侧耳素化合物、其药物组合物、合成方法与用途 |
| ES2553929B1 (es) * | 2014-06-11 | 2016-09-26 | Antonio Javier MORENO CASTRO | Dispositivo de modificación/destrucción selectiva de tejidos orgánicos |
| BR112017026904B1 (pt) | 2015-06-17 | 2023-10-10 | Nabriva Therapeutics GmbH | Formulações farmacêuticas injetáveis de lefamulina, e seu uso |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| CN116077455A (zh) | 2015-06-18 | 2023-05-09 | 埃斯特拉有限责任公司 | 含雌四醇组分的口腔分散剂量单位 |
| TWI762573B (zh) | 2017-02-10 | 2022-05-01 | 奧地利商納畢瓦治療有限責任公司 | 截短側耳素之純化 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| CN111170911A (zh) * | 2019-09-29 | 2020-05-19 | 安帝康（无锡）生物科技有限公司 | 用于治疗细菌感染性疾病的截短侧耳素类化合物 |
| CN111170893B (zh) * | 2020-01-19 | 2022-04-26 | 郑州依米花手性药物研究有限公司 | Lefamulin的中间体化合物及其在Lefamulin制备中的应用 |
| CN115397407A (zh) * | 2020-04-17 | 2022-11-25 | 纳布里瓦治疗有限责任公司 | 截短侧耳素类化合物的新治疗用途 |
| US20230174509A1 (en) | 2020-04-17 | 2023-06-08 | Nabriva Therapeutics GmbH | Therapeutic use of pleuromutilins |
| CA3180535A1 (en) * | 2020-04-17 | 2021-10-21 | Nabriva Therapeutics GmbH | Therapeutic use of pleuromutilins |
| WO2023152115A1 (en) | 2022-02-09 | 2023-08-17 | Nabriva Therapeutics GmbH | Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria |
| EP4338732A1 (en) | 2022-09-16 | 2024-03-20 | Nabriva Therapeutics GMBH | Lefamulin and its derivatives for use in the treatment of tularemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4130709A (en) * | 1977-12-08 | 1978-12-19 | Eli Lilly And Company | Pleuromutilin glycoside derivatives |
| DE4023848C2 (de) | 1990-07-27 | 1994-04-21 | Huels Chemische Werke Ag | Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern |
| GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| GB0017031D0 (en) * | 2000-07-11 | 2000-08-30 | Biochemie Gmbh | Antimicrobials |
| GB0207495D0 (en) | 2002-03-28 | 2002-05-08 | Biochemie Gmbh | Organic compounds |
| GB0209262D0 (en) | 2002-04-23 | 2002-06-05 | Biochemie Gmbh | Organic compounds |
| EP1534678B1 (en) * | 2002-07-24 | 2007-10-31 | Nabriva Therapeutics Forschungs GmbH | Pleuromutilin derivatives as antimicrobbials |
| EP2298733B1 (en) * | 2005-06-27 | 2016-05-25 | Nabriva Therapeutics AG | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| GB0513058D0 (en) * | 2005-06-27 | 2005-08-03 | Sandoz Ag | Organic compounds |
| GB0515995D0 (en) * | 2005-08-03 | 2005-09-07 | Sandoz Ag | Organic compounds |
| EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
-
2007
- 2007-03-20 EP EP07450053A patent/EP1972618A1/en not_active Withdrawn
- 2007-07-25 US US11/828,224 patent/US20090118366A1/en not_active Abandoned
-
2008
- 2008-03-19 ES ES08714294T patent/ES2375503T3/es active Active
- 2008-03-19 EA EA200970868A patent/EA018707B1/ru unknown
- 2008-03-19 PL PL08714294T patent/PL2137143T3/pl unknown
- 2008-03-19 PT PT110058633T patent/PT2380874T/pt unknown
- 2008-03-19 DK DK08714294.9T patent/DK2137143T3/da active
- 2008-03-19 PT PT08714294T patent/PT2137143E/pt unknown
- 2008-03-19 EP EP11005863.3A patent/EP2380874B1/en active Active
- 2008-03-19 MY MYPI20093722A patent/MY148916A/en unknown
- 2008-03-19 NZ NZ579011A patent/NZ579011A/en unknown
- 2008-03-19 KR KR1020097018920A patent/KR101478593B1/ko active IP Right Grant
- 2008-03-19 SI SI200830451T patent/SI2137143T1/sl unknown
- 2008-03-19 ES ES11005863.3T patent/ES2620459T3/es active Active
- 2008-03-19 AU AU2008229609A patent/AU2008229609B2/en active Active
- 2008-03-19 UA UAA200910582A patent/UA97836C2/ru unknown
- 2008-03-19 ZA ZA200905590A patent/ZA200905590B/xx unknown
- 2008-03-19 CA CA2678795A patent/CA2678795C/en active Active
- 2008-03-19 EP EP08714294A patent/EP2137143B1/en active Active
- 2008-03-19 CN CN201410406131.XA patent/CN104211624B/zh active Active
- 2008-03-19 WO PCT/AT2008/000097 patent/WO2008113089A1/en active Application Filing
- 2008-03-19 CN CN200880007780.5A patent/CN101668738B/zh active Active
- 2008-03-19 AT AT08714294T patent/ATE523486T1/de active
- 2008-03-19 US US12/531,839 patent/US8071643B2/en active Active
- 2008-03-19 JP JP2009553863A patent/JP5479114B2/ja active Active
- 2008-03-19 DK DK11005863.3T patent/DK2380874T3/en active
- 2008-03-19 BR BRPI0809023A patent/BRPI0809023B8/pt active IP Right Grant
- 2008-03-20 TW TW097109871A patent/TWI406657B/zh active
-
2009
- 2009-08-17 IL IL200440A patent/IL200440A/en active IP Right Grant
- 2009-08-19 TN TNP2009000347A patent/TN2009000347A1/fr unknown
- 2009-10-15 MA MA32283A patent/MA31314B1/fr unknown
-
2010
- 2010-06-25 HK HK10106270.6A patent/HK1140185A1/xx unknown
-
2011
- 2011-10-04 US US13/252,732 patent/US8153689B2/en active Active
- 2011-11-22 HR HR20110869T patent/HRP20110869T1/hr unknown
- 2011-12-02 CY CY20111101198T patent/CY1117482T1/el unknown
-
2012
- 2012-04-03 US US13/438,160 patent/US20130040954A1/en not_active Abandoned
-
2014
- 2014-02-12 JP JP2014024500A patent/JP5893651B2/ja active Active
- 2014-05-21 US US14/283,734 patent/US20140256731A1/en not_active Abandoned
-
2017
- 2017-04-06 US US15/480,756 patent/US20170266194A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,880 patent/US20180303842A1/en not_active Abandoned
-
2019
- 2019-02-15 US US16/277,143 patent/US20190175603A1/en not_active Abandoned
- 2019-10-04 US US16/593,449 patent/US20200030335A1/en not_active Abandoned
-
2020
- 2020-05-22 US US16/881,117 patent/US20200281933A1/en not_active Abandoned
- 2020-09-16 CY CY2020032C patent/CY2020032I2/el unknown
- 2020-10-01 FI FIC20200038C patent/FIC20200038I1/fi unknown
- 2020-10-22 LT LTPA2020531C patent/LTPA2020531I1/lt unknown
- 2020-12-30 US US17/138,097 patent/US20210113571A1/en not_active Abandoned
-
2021
- 2021-01-04 NL NL301086C patent/NL301086I2/nl unknown
- 2021-01-12 HU HUS2100001C patent/HUS2100001I1/hu unknown
- 2021-01-15 NO NO2021002C patent/NO2021002I1/no unknown
-
2022
- 2022-03-23 US US17/702,304 patent/US20220218713A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020032I2 (el) | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια | |
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| CY2017010I2 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
| BRPI0917675A2 (pt) | compostos orgânicos para cura de ferida | |
| BRPI1012247A2 (pt) | compostos inseticidas | |
| BRPI1015931A2 (pt) | Compostos inseticidas | |
| DK2300443T3 (da) | Triazolderivater, der er anvendelige til behandling af sygdomme | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| SMT201600131B (it) | Procedimento per la produzione di piastrine | |
| DK2222272T3 (da) | Behandling af luftvejssygdom | |
| BRPI0906618A2 (pt) | Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta | |
| BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
| DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
| BRPI1013941A2 (pt) | compostos inseticidas | |
| DK2271618T3 (da) | Farmaceutiske forbindelser | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| EE201300004A (et) | Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks | |
| DK2296651T3 (da) | 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme | |
| BRPI0915130A2 (pt) | derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c |